Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707524 | 0.84 | GSK3B (0.58) | GSK3BVNN1MRGPRX4ADRA1DGPR35 | |
| SCHEMBL9821033 | 0.84 | GSK3B (0.39) | GSK3BVNN1MRGPRX4ADRA1DGPR35 | |
| SCHEMBL1448228 | 0.80 | TPMT (0.54) | GSK3BTPMTTSHRRAB9A | |
| SCHEMBL5223887 | 0.79 | VNN1 (0.40) | GSK3BVNN1MRGPRX4ADRA1DGPR35 | |
| SCHEMBL2565282 | 0.79 | TPMT (0.61) | VNN1MRGPRX4GPR35TPMTTSHR | |
| SCHEMBL11069556 | 0.79 | GSK3B (0.40) | GSK3BVNN1GPR35ALDH1A1MAPT | |
| SCHEMBL24156534 | 0.78 | PARP1 (0.46) | VNN1MRGPRX4ADRA1DGPR35TPMT | |
| SCHEMBL16953692 | 0.78 | MAPT (0.45) | VNN1MRGPRX4ADRA1DGPR35TPMT | |
| SCHEMBL19707525 | 0.76 | MAPT (0.47) | VNN1MRGPRX4ALDH1A1LMNAMAPT | |
| SCHEMBL3488915 | 0.74 | ALDH1A1 (0.46) | VNN1MRGPRX4GPR35ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910742-B2 | Survivin inhibitors | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070072833-A1 | Survivin inhibitors | ABBVIE INC. | 2007-03-29 | — | — | US | disclosed |
| EP-0834510-B1 | Flavone derivative and medicine comprising the same | KOWA CO (JP) | 2005-02-23 | — | — | EP | disclosed |
| EP-0902007-B1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-6136848-A | ANTIALLERGENS; ASTHMA THERAPY | KOWA CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6046212-A | ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0902007-A1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0834510-A2 | Flavone derivative and medicine comprising the same | KOWA CO. LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072833-A1 | Survivin inhibitors | XIAP, BIRC5, BIRC3 | GSK3B 520/4885VNN1 3719/4885MRGPRX4 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.